In the studies using antibodies against endoglin, significant tumor growth delay and anti-metastatic action was achieved [17,31], resulting already in phase I clinical trials for the treatment of cancer with the TRC105 anti-endoglin antibody [16,32,33]. This evidence concerns the gene ENG and cancer.